

Esophageal Pathology Testing

Policy Number: AHS – M2171 – Esophageal Pathology Testing	Policy Revision Date: 07/01/2025 Initial Policy Effective Date: 12/01/2024
---	---

[POLICY DESCRIPTION](#) | [RELATED POLICIES](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [TABLE OF TERMINOLOGY](#) | [SCIENTIFIC BACKGROUND](#) | [GUIDELINES AND RECOMMENDATIONS](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

I. Policy Description

The esophagus is a long tube that serves to connect the mouth to the stomach. Although the esophagus is primarily a connecting organ, it experiences significant chemical and mechanical trauma. The esophagus has mechanisms and structures to withstand this damage, but molecular injury is common.¹ Both serological and genetic markers have been suggested to identify, diagnose, or assess risk in the esophagus.

Eosinophilic esophagitis (EoE) is one such condition, as its nonspecific symptoms (pain, issues swallowing, vomiting, and so on) may be accompanied by inflammatory markers in the esophagus.² Similarly, esophageal cancer is characterized by several nonspecific symptoms, while a predecessor condition, Barrett’s esophagus (BE), may have no clinical symptoms at all.^{3,4}

For guidance concerning Tumor Mutational Burden Testing (TMB) and/or Microsatellite instability (MSI) analysis please refer to the AHS-M2178-Microsatellite Instability and Tumor Mutational Burden Testing policy.

II. Related Policies

Policy Number	Policy Title
AHS-M2078	Genetic Testing for Germline Variants of the RET Proto-Oncogene
AHS-M2178	Microsatellite Instability and Tumor Mutational Burden Testing

III. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the “Applicable State and Federal Regulations” section of this policy document.

- 1) For individuals who have been newly diagnosed with cancer of the esophagus or esophagogastric junction (EGJ), mismatch repair (MMR) analysis by immunohistochemistry (IHC) **MEETS COVERAGE CRITERIA.**
- 2) For individuals who have been diagnosed with locally advanced, recurrent, or metastatic cancer of the esophagus or EGJ and for whom PD-1 inhibitor treatment is being considered, tumor analysis of PD-L1 expression by IHC **MEETS COVERAGE CRITERIA.**
- 3) For individuals who have been diagnosed with inoperable locally advanced, recurrent, or metastatic adenocarcinoma of the esophagus or EGJ and for whom trastuzumab or an approved biologic or

biosimilar drug to trastuzumab is being considered for first-line therapy, HER2 overexpression testing by IHC, fluorescence in situ hybridization (FISH), or other in situ hybridization (ISH) methodology **MEETS COVERAGE CRITERIA.**

- 4) For individuals diagnosed with unresectable locally advanced, recurrent, or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or EGJ and for whom one of the following drugs is being considered as a second-line therapy, the corresponding gene testing **MEETS COVERAGE CRITERIA:**
 - a) Larotrectinib or entrectinib: *NTRK* gene fusion.
 - b) Selpercatinib: *RET* gene fusion.
 - c) Dabrafenib or trametinib: *BRAF* V600E mutation.
- 5) The use of genetic testing (e.g., molecular panel tests, gene expression profiling) to diagnose or monitor an individual with eosinophilic esophagitis (EoE) or to assess the risk of an individual developing EoE **DOES NOT MEET COVERAGE CRITERIA.**
- 6) For the diagnosis and evaluation of Barrett’s esophagus, low-grade esophageal dysplasia, or high-grade esophageal dysplasia, wide-area transepithelial sampling (WATS) **DOES NOT MEET COVERAGE CRITERIA.**

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual’s illness.

- 7) Assessing for risk of Barrett’s esophagus and/or esophageal, including esophagogastric junction, cancer using a molecular classifier (e.g., BarreGEN test) **DOES NOT MEET COVERAGE CRITERIA.**
- 8) Epigenetic analysis for the likelihood for Barrett’s esophagus, esophageal, or esophagogastric junction cancer (e.g., methylation analysis, EsoGuard) **DOES NOT MEET COVERAGE CRITERIA.**
- 9) To diagnose, assess, or monitor eosinophilic esophagitis (EoE), the Esophageal String Test **DOES NOT MEET COVERAGE CRITERIA.**
- 10) For esophageal and esophagogastric junction cancers, cell-free DNA/circulating tumor DNA (cfDNA/ctDNA) testing **DOES NOT MEET COVERAGE CRITERIA.**

NOTES:

Note: For two or more gene tests being run on the same platform, please refer to AHS-R2162 Reimbursement Policy.

IV. Table of Terminology

Term	Definition
ACG	American College of Gastroenterology
AFS	American Foregut Society
AMACR	Alpha-methylacyl-CoA racemase

APC	<i>Adenomatous polyposis coli</i>
ARID1A	<i>AT-rich interactive domain-containing protein 1A</i>
ARID2	<i>AT-rich interactive domain 2</i>
ASGE	American Society for Gastrointestinal Endoscopy
BAT	Bethesda marker
BE	Barrett's esophagus
BLM	Bloom syndrome protein
BMJ	British Medical Journal
BS	Bloom syndrome
CAPN14	<i>Calpain 14</i>
CCL26	<i>C-C motif chemokine ligand 26</i>
CCNA1	<i>Cyclin A1</i>
cfDNA	Cell-free tumor DNA
CLIA '88	Clinical Laboratory Improvement Amendments Of 1988
CMM1	Familial cutaneous malignant melanoma-1
CMS	Centers For Medicare and Medicaid Services
COX2	<i>Cyclooxygenase 2</i>
CPS	Combined Positive Score
CSCO	Chinese Society of Clinical Oncology
CTC	Circulating tumor cell
ctDNA	Circulating tumor deoxyribonucleic acid
DCC	<i>Deleted in colorectal carcinoma</i>
DNA	Deoxyribonucleic acid
DOCK2	<i>Dedicator of cytokinesis 2</i>
EAACI	European Academy of Allergy and Clinical Immunology
EAC	Esophageal adenocarcinoma
ED	Esophageal dysplasia
EDP	Eosinophilic esophagitis diagnostic panel
EGFR	<i>Epidermal growth factor receptor</i>
EGJ	Esophagogastric junction
ELISA	Enzyme-linked immunoassay
ELMO1	<i>Engulfment and cell motility protein 1</i>
EoE	Eosinophilic esophagitis
ESMO	European Society for Medical Oncology
ESPGHAN	European Society of Pediatric Gastroenterology, Hepatology And Nutrition
EST	Esophageal string test
EUREOS	European Society of Eosinophilic Oesophagitis
FA	Fanconi anemia
FANC	Fanconi anemia complementation group A
FB	Forceps biopsy
FBE	Familial Barrett's esophagus
FDA	Food and Drug Administration
FISH	Fluorescence in situ hybridization
GERD	Gastroesophageal reflux disease
HER2	<i>Human epidermal growth factor receptor 2</i>

HGD	High-grade dysplasia
HGD/EAC	High-grade dysplasia/esophageal adenocarcinoma
HIF1-ALPHA	Hypoxia-inducible factor 1-alpha
<i>HoGG1</i>	<i>8-oxoguanine DNA glycosylase</i>
ICER	Incremental cost-effectiveness ratio
IgE	Immunoglobulin E
IHC	Immunohistochemistry
IND	Indefinite for dysplasia
JSMO	Japanese Society of Medical Oncology
K2O	Potassium oxide
KSMO	Korean Society of Medical Oncology
LDTs	Laboratory-developed tests
LGD	Low-grade dysplasia
MBP-1	Major basic protein 1
<i>MCC</i>	<i>Colorectal mutant cancer protein</i>
ML	Mutational load
MMR	Mismatch repair
MSI	Microsatellite instability
MSI-H	High microsatellite instability
<i>MXI1</i>	<i>Max-interacting protein 1</i>
NBDE	Non-dysplastic intestinal metaplasia
NCCN	National Comprehensive Cancer Network
NDBE	Baseline nondysplastic BE
NF2	Neurofibromatosis type 2
NME1	Nucleoside Diphosphate Kinase 1
NNT	Number needed to test
<i>NOTCH3</i>	<i>Notch receptor 3</i>
NTRK	Neurotrophic tyrosine receptor kinase
PCR	Polymerase chain reaction
PD-1	Programmed death-1
PD-L1	Programmed death-ligand 1
PPK	Palmoplantar keratoderma
<i>PRG2</i>	<i>Proteoglycan 2, pro eosinophil major basic protein</i>
<i>PSEN2</i>	<i>Presenilin 2</i>
<i>PTEN</i>	<i>Phosphatase and TENsin homolog</i>
QALY	Quality-adjusted life-year
<i>RB</i>	<i>Retinoblastoma protein</i>
<i>RHBDF2</i>	<i>Rhomboid 5 homolog 2</i>
<i>RNF43</i>	<i>Ring finger protein 43</i>
SAGES	Society of American Gastrointestinal and Endoscopic Surgeons
SCC	Squamous cell carcinoma
<i>SMAD4</i>	<i>SMA- and MAD-related protein 4</i>
<i>SMARCA4</i>	<i>Matrix associated, actin dependent regulator of chromatin, subfamily a</i>
SOC	Standard-of-care
<i>SPG20</i>	<i>Spastic paraplegia 20</i>

SSO	Sequence-specific oligonucleotide
STMN1	Stathmin 1
TAVAC	Technology And Value Assessment Committee
<i>TFF1</i>	<i>Trefoil factor 1</i>
TML	Tumor mutational load
<i>TNFAIP8</i>	<i>TNF alpha induced protein 8</i>
TOS	Thoracic outlet syndromes
<i>TP53</i>	<i>Tumor protein 53</i>
TPS	Tumor positive score
TRK	Tropomyosin receptor kinase
<i>TSLP</i>	<i>Thymic stromal lymphopoietin</i>
TVAC	Technology And Value Assessment Committee
UEG	United European Gastroenterology
VHL	Von hippel-lindau syndrome
VIM	Vimentin
WATS	Wide-Area Transepithelial Sampling
WATS3D	Wide-Area Transepithelial Sampling with Computer-Assisted 3-Dimensional Analysis

V. Scientific Background

The esophagus is a long tube that connects the mouth to the stomach. Its primary function is to transport food from the mouth to the stomach. However, this organ is often exposed to difficult conditions, from abrasive food to the acidic conditions of the stomach. Although mechanisms are in place to protect against injury (namely the tough squamous cells), it is common to see injury or disease in the esophagus.¹

Many serological and genetic markers have been proposed as tools to assist in evaluation of esophageal pathology. Eosinophilic esophagitis (EoE), Barrett’s esophagus (BE), and esophageal cancer are typically diagnosed with histological analysis from endoscopic biopsy,²⁻⁴ but biopsies frequently require careful consideration and resources to perform properly.⁵ For these reasons, serum and genetic markers have been suggested as noninvasive markers for esophageal pathologies.

Eosinophilic Esophagitis (EoE)

Eosinophilic esophagitis (EoE) is marked by the presence of eosinophils in the esophagus. Eosinophils are typically associated with mitigating inflammation but are not normally found in the esophagus. EoE is represented by a broad set of clinical symptoms, such as difficulty swallowing, chest, or abdominal pain, and feeding dysfunction. Diagnosis is established through endoscopy with biopsies to confirm eosinophilia. The current diagnostic criteria set the cutoff for eosinophilia at ≥ 15 eosinophils per high-power field, (60 eosinophils per mm^2) although this figure has been heavily discussed.^{2,6}

Proprietary Testing- EoE

Laboratory tests have been suggested as a noninvasive adjunct for EoE. Serum IgE will be elevated in up to 60% of EoE patients, as allergy has a strong association with EoE. Many other markers, such as eotaxin-3, major basic protein-1, tryptase, chemokines, and serum eosinophil count, have all been suggested to assist in evaluation of EoE.^{2,6} Immune system factors may also contribute to pathology. Since eosinophils are not normally found in the esophagus, their presence in the esophagus may suggest an underlying issue with the immune system. Various interleukins, mast cells, and T cells have all been proposed as

contributing to pathogenesis, but the exact pathway and mechanisms are not completely understood.⁷ Genetic features have also been used for EoE evaluation. Twin studies and family histories have indicated a role for genetics in EoE. Several genes have also been identified as potential risk factors, such as *CAPN14* (an interleukin-13 regulator), *TSLP* (a basophil regulator), and *CCL26* (promotes eosinophil movement into esophagus).⁸

Wen, et al. (2013) developed a diagnostic gene expression panel (“EDP”) for EoE. The authors identified candidate genes using two cohorts of EoE and control patients, then validated these genes with a separate cohort of 194 patients (91 active EoE, 57 control, 34 ambiguous, 12 reflux). The panel was found to identify EoE patients at 96% sensitivity and 98% specificity. The authors also noted that the panel could separate patients in remission from unaffected patients.⁹

Shoda, et al. (2018) used an “EoE Diagnostic Panel” (EDP) to further classify EoE cases by histologic, endoscopic, and molecular features. The EDP consisted of 95 esophageal transcripts purported to identify EoE among both unaffected patients and patients with other conditions. A total of 185 biopsies were studied. The authors identified three clear subtypes of EoE; subtype 1 with a normal-appearing esophagus and mild molecular changes, subtype 2 with an inflammatory and steroid-responsive phenotype, and subtype 3 with a “narrow-caliber” esophagus and severe molecular alterations. These findings were replicated in a 100-biopsy sample.¹⁰

Tests are commercially available for EoE. Noninvasive tests (as an alternative to endoscopy) have been recently popular. The Esophageal String Test is one such alternative. The patient swallows a gelatin-coated capsule with a string wrapped inside. Once the capsule is in the patient’s stomach, the gelatin dissolves, allowing the capsule to pass through. The string itself is used to collect samples from the patient’s esophagus and is easily removed from the patient. From there, the sample is analyzed for several biomarkers (major basic protein-1, eotaxins 2 and 3, and so on) to provide a probability% (a trademarked “EoScore”) of esophageal inflammation.^{11,12}

Barrett’s Esophagus (BE)

Barrett’s esophagus (BE) is a condition in which the normal squamous tissue lining the esophagus is replaced by metaplastic columnar epithelium. This new epithelium contains gastric features and is typically caused by chronic gastroesophageal reflux disease (GERD). This condition predisposes to esophageal cancer. When noxious substances (gastric acid, bile, et al) are exposed to the squamous esophageal tissue, the damage is usually repaired through regeneration of these squamous cells. In BE cases, this damage is repaired not through creation of new squamous cells, but through metaplastic columnar cells. The exact reason for this is unknown. Although these metaplastic cells are more resistant to reflux-based damage than the normal squamous cells, these cells frequently show the oxidative DNA damage that is typical of cancer. Mutations in the p53 tumor suppressor gene appear to be the catalyst for cancers, as acquisition of this mutation in conjunction with the replication of the genome is conducive to carcinogenesis.³

Vollmer (2019) performed a review assessing incidence of adenocarcinoma detected during surveillance of BE. The author identified 55 studies encompassing 61371 total patients. Of the 61371 total patients, 1106 developed adenocarcinoma. Overall, the author found that the model created from the studies “predicted the per-person probability of developing cancer in five years of complete follow-up is approximately 0.0012.” Variables affecting this probability included mean time of follow-up, definition of Barrett metaplasia, and fraction of patients followed up for at least five years.¹³

Proprietary Testing- BE

Proprietary tests are commercially available for assessment of BE, usually to evaluate risk (BE progression to cancer, risk of BE itself, and such). For example, BarreGen, offered by Interpace Diagnostics, uses tumor mutational load (a measure intended to capture total genomic instability of a sample) to calculate risk of progression. Although many ways can estimate mutational load, BarreGen tests ten key genomic loci which are as follows: “1p (*CMM1*, L-myc), 3p (*VHL*, *HoGG1*), 5q (*MCC*, *APC*), 9p (*CDKN2A*), 10q (*PTEN*, *MXI1*), 17p (*TP53*), 17q (*RNF43*, *NME1*), 18q (*SMAD4*, *DCC*), 21q (*TFF1*, *PSEN2*) and 22q (*NF2*).” These loci encompass integral tumor suppressors and are proposed to provide an accurate picture of genomic instability.^{14,15}

Another test, TissueCypher, also proposes to predict likelihood of progression from BE to esophageal cancer. The test measures nine protein biomarkers that represent morphological and cellular changes (p53, p16, AMACR, CD68, COX2, HER2, K20, HIF1-alpha, CD45RO). These biomarkers are quantified and converted to a risk score (1-10) and probability of progression.¹⁶

Esoguard, by Lucid Diagnostics, is an esophageal DNA test which analyzes 31 methylated biomarkers in the diagnosis of non-dysplastic Barrett’s esophagus and adenocarcinoma. The assay uses next generation sequencing to examine individual DNA molecules for the presence or absence of cytosine methylation with a 90% specificity and 90% sensitivity.¹⁷

Finally, a proprietary imaging system, WATS3D, is commercially available. This imaging system samples from a wider area, as opposed to only taking focal samples in a traditional biopsy. This technology also provides a 3-dimensional image of the sampled area. This technology purports to provide more precise sampling than the traditional 4-quadrant biopsies, claiming an increased detection rate of BE and other dysplasias. “WATS3D increased the overall detection of esophageal dysplasia by 242% and Barrett’s by 153%.”¹⁸

Esophageal Cancer

Esophageal cancers are largely divided into two groups: squamous cell carcinomas (SCCs) and adenocarcinomas (EAC). SCCs usually begin in the middle of the esophagus, whereas EACs often originate near the gastroesophageal junction. Both share several risk factors, such as smoking. Due to the numerous environmental risk factors for both types of cancer, it is difficult to ascertain the true impact of genetic factors.¹⁹ These cancers are primarily diagnosed through histologic examination, usually obtained through endoscopy.⁴

Advancements have been in the molecular characterization of both types of cancer. *TP53* mutations are the most common mutation seen in both types of cancer. Other frequently mutated genes in adenocarcinoma include *ELMO1* and *DOCK2* (enhance cell motility), *ARID1A*, *SMARCA4* and *ARID2* (chromatin remodelers), and *SPG20* (traffics growth factor receptors). BE, as the precursor to adenocarcinomas, includes certain similarities in genetic mutations but at a less severe rate. Further, the rate of overlap tended to increase with higher degree of dysplasia.²⁰

Squamous cell carcinoma mutations tend to be in genes associated with specific cellular pathways. Genes in ubiquitous pathways, such as *EGFR*, *NOTCH3*, and *RB*, are frequently mutated in SCC. The molecular profile of esophageal SCC tends to align more with other squamous cell cancers (such as head and neck cancers) rather than EAC.²⁰ Numerous gene expression studies have been performed to further

classify molecular subtypes of esophageal cancer.²¹⁻²³ Gene expression profiles may have utility in assessing response to treatment, prognosis, or risk assessment.

Historically, Carcinoembryonic Antigen (CEA) has been used as the serum cancer marker in the diagnosis of esophageal cancer, as CEA levels have been shown to be significantly higher in these patients. The sensitivity (8-70%), specificity (57-100%), and positive likelihood ratio (5.94) of CEA means that patients with EC have a 6-fold higher chance of having higher CEA levels. Other markers include squamous cell cancer antigen (SCC-Ag) and cytokeratin 21-1 fragment (CYFRA21-1). The sensitivity and specificity of Cyfra21-1 ranged from 36% to 63% and from 89% to 100%, respectively, with patients having a 12-fold higher chance of having EC. The sensitivity and specificity of SCC-Ag ranged from 13% to 64% and from 91% to 100%, respectively, whereas its PLR was 7.66.²⁴

Li, et al. (2019) investigated potential biomarkers for lymph node metastasis for esophageal squamous cell carcinoma. Six studies encompassing 70 patients were included. The authors identified nine biomarkers and four cellular mechanisms that influence lymph node metastasis. From there, they identified three biomarkers with broader influence on prognosis of disease, *PTEN*, *STMN1*, and *TNFAIP8*. The authors suggested that those three biomarkers should be researched further.²⁵

Plum, et al. (2019) evaluated *HER2* overexpression's impact on prognosis of esophageal adenocarcinoma (EAC). A total of 428 EAC patients that underwent a "transthoracic thoraco-abdominal esophagectomy" were included. The authors identified 44 patients with *HER2* positivity (IHC score 3+ or 2+ with gene amplification). This cohort was found to have a better overall survival (OS, 70.1 months vs 24.6 months), along with better histology, absence of lymphatic metastases, and lower tumor stages. The authors also noted a similarity in results to a large 2012 study.²⁶

Frankell, et al. (2019) examined the molecular landscape of esophageal adenocarcinoma (EAC). The authors assessed 551 genomically characterized EACs. A total of 77 driver genes and "21 non-coding driver elements" were identified. The authors also found an average of 4.4 driver events per tumor. A three-way association was found, between hyper-mutation, *Wnt* signaling, and loss of immune signaling genes. Finally, the authors also identified "sensitizing events" (events causing a tumor to be more susceptible to a therapy) to CD4/6 inhibitors in over half of the EAC cases studied.²⁷

Clinical Utility and Validity

Ackerman, et al. (2019) evaluated the ability of the 1-hour Esophageal String Test to distinguish between active eosinophilic esophagitis (EoE), inactive eosinophilic esophagitis, and normal esophagi. A total of 134 patients (62 active EoE, 37 inactive EoE, 35 normal) were included. The authors found that eotaxin 3 measured from both EST samples and the control biopsy extracts to be the best marker for distinguishing active EoE from inactive EoE (by both sensitivity and specificity). Addition of major basic protein 1 (MBP-1) improved sensitivity by 0.039 (0.652 to 0.693) and specificity by 0.014 (0.261 to 0.275) across all patients.¹¹

Hao, et al. (2019) performed a cost-effectiveness analysis of an "adenocarcinoma risk prediction multi-biomarker assay" (TissueCypher's Barrett's Esophagus Assay). A hypothetical cohort of 10000 patients with BE diagnoses (including non-dysplastic intestinal metaplasia [NBDE], indefinite for dysplasia [IND], and low-grade dysplasia [LGD]) was created. A Markov decision model was used to compare BE management costs between assay use and the standard-of-care (SOC). A surveillance interval of five years was used. Low-risk patients were found to have a 16.6% reduction in endoscopies. High-risk

patients were found to have a 58.4% increase in endoscopic treatments (compared to the SOC arm), leading to a death total of 111 for the assay arm compared to 204 in the SOC arm (a 45.6% reduction). Overall, the authors calculated the incremental cost-effectiveness ratio (ICER) to be \$52,483/quality-adjusted life-year (QALY), and they found that “the probability of the Assay being cost-effective compared to the SOC was 57.3% at the \$100,000/QALY acceptability threshold.”²⁸

Eluri, et al. (2018) aimed to validate a genomic panel intended to represent tumor mutational load (TML). Previously, the authors evaluated a panel of ten genomic loci from which a TML score was calculated. This mean TML was found to be significantly higher in 23 BE patients that had progressed to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) as compared to 46 that had not progressed. The area under the curve in this prior study was found to be 0.95 at a mutational load (ML) cutoff of one (on a scale of 1-10). In the present study, 159 subjects were included. Cases had “baseline nondysplastic BE (NDBE) and developed HGD/EAC \geq 2 years later.” 58 subjects were progressors and 101 were nonprogressors. The authors identified no difference in mean ML in pre-progression tissue in both cohorts (ML = 0.73 ± 0.69 vs. ML = 0.74 ± 0.61). The area under the curve at the cutoff of ML 1 was only 0.50, and the authors concluded that the “utility of the ML to stratify BE patients for risk of progression was not confirmed in this study.”²⁹

Trindade, et al. (2019) evaluated tumor mutational load’s ability to “risk-stratify those that may progress from non-dysplastic BE to dysplastic disease.” A total of 28 patients were included, and ML levels were compared between those that progressed to dysplasia and those who had not. Eight total patients progressed to dysplasia (6 low-grade, 2 high-grade), and seven of these patients had “some level” of genomic stability detected (ML \geq 5 on a scale of one to 10). Ten of the 20 patients that did not progress to dysplasia had “no” ML level. The authors also noted that at an ML of \geq 1.5, the risk of progression to high-grade dysplasia was 33%, with a sensitivity of 100% and specificity of 85%. The authors concluded “that ML may be able to risk-stratify progression to high-grade dysplasia in BE-IND. Larger studies are needed to confirm these findings.”¹⁵

Moinova, et al. (2018) evaluated the ability of two DNA methylation signatures to detect BE. Methylation signatures of the *VIM* and *CCNA1* loci were evaluated in 173 patients with or without BE. *CCNA1* methylation was found to have an area under the curve of 0.95 for distinguishing BE-related dysplasia compared to normal esophagi. When the data for *VIM* methylation was added, the resulting sensitivity was 95%, and the resulting specificity was 91%. These findings were replicated in a validation cohort of 86 patients, with the combination of methylation markers detecting BE metaplasia at 90.3% sensitivity and 91.7% specificity.³⁰

Critchley-Thorne, et al. (2016) validated a pathology panel to predict progression of BE to esophageal cancer. The authors identified 15 potential biomarkers, which were evaluated in both training and validation sets. This “classifier” separated patients into three different risk classes: low, intermediate, and high in the training set of 183. The authors calculated the hazard ratio of intermediate to low risk at 4.19 and high to low at 14.73. In the validation set (n = 183), the concordance index (an estimation of area under the curve) of the 15-factor classifier was 0.772, the best of the amounts tested (3, 6, 9, 12, 15, 17). The authors also noted that this classifier provided independent prognostic information that were outperformed predictions based on other clinicopathological factors, such as segment length, age, and p53 overexpression.³¹

Another multicenter study investigated the use of WATS^{3D} with either random or targeted FB in the detection of esophageal dysplasia (ED). A total of 12,899 patients were enrolled in the study, and WATS^{3D}

detected an additional 213 cases of ED beyond the initial 88 cases identified by FB, representing an increase of 242%. Regarding screening for BE, WATS increased the overall detection by 153% (from 13.1% to 33% of the individuals enrolled). The authors noted that the order of testing (e.g., FB or WATS) did not impact the results. The authors conclude, “In this study, comprised of the largest series of patients evaluated with WATS, adjunctive use of the technique with targeted and random FB markedly improved the detection of both ED and BE. These results underscore the shortcomings of FB in detecting BE-associated neoplasia, which can potentially impact the management and clinical outcomes of these patients.”³²

A study into the cost-effectiveness of WATS^{3D} testing as an adjunct to the standard-of-care forceps biopsy (FB) used a reference case of a 60-year-old individual with GERD to see the number of screens needed to avert one cancer and one cancer-related death as well as to calculate the QALYs as measured in 2019 U.S. dollars. With this as a reference case, 320 – 337 individuals would need to be screened using WATS^{3D} to avert one cancer, and 328 – 367 individuals would be required to avert one death. The additional cost associated with WATS^{3D} was \$1219, but an additional 0.017 QALYs were produced, resulting in an ICER of \$71395/QALY. The authors concluded that screening for BE in certain GERD patients “is more cost-effective when WATS^{3D} is used adjunctively to the Seattle protocol than with the Seattle protocol alone.”³³

One study compared the use of the WATS^{3D} technology to standard forceps biopsy. A total of 117 individuals with a history of Barrett’s esophagus with dysplasia had both techniques performed. For the biopsy, a four-quadrant biopsy quadrant protocol was performed every 1 – 2 cm. Evaluation of the biopsy and the WATS^{3D} technique was performed by separate pathologists, blinded to each other’s results. Moreover, “Brush biopsy [WATS^{3D}] added an additional 16 position cases increasing the yield of dysplasia detection by 42% (95% CI: 20.7 – 72.7). The number needed to test (NNT) to detect one additional case of dysplasia was 9.4 (95% CI: 6.4 – 17.7).” The authors of the study noted that no statistical difference was evident between medical centers, the type of forceps used, or between sampling every 1 cm versus every 2 cm. They conclude, “These data suggest that computer-assisted brush biopsy is a useful adjunct to standard endoscopic surveillance regimens for the identification of dysplasia in Barrett’s esophagus.”³⁴

Another multicenter prospective trial of 4203 patients studied the use of WATS^{3D} as an adjunct to four-quadrant random forceps biopsy in detecting Barrett’s esophagus and esophageal dysplasia. FB alone detected 594 cases of BE, and the addition of WATS^{3D} detected an additional 493 cases, an increase of 83%. Likewise, WATS^{3D} detected an increase of 88.5% of low-grade dysplasia (LGD). The authors concluded that “Adjunctive use of WATS to FB significantly improves the detection of both BE and ED. Sampling effort, an inherent limitation associated with screening and surveillance, can be improved with WATS allowing better informed decisions to be made about the management and subsequent treatment of these patients.”³⁵ These findings support the earlier study by Johanson and colleagues. In their study of 1266 patients being screened for BE and ED, they noted an overall increase of 39.8% in the detection of BE when WATS^{3D} (brush biopsy or BB) was used as an adjunct to FB. They also report that the number of patients needed to test to obtain a positive BE result was 8.7. Interestingly, specifically for patients with GERD, the addition of WATS^{3D} resulted in an even higher increase in the detection of BE (by 70.5%).³⁶

Vennalaganti, et al. (2018) published a randomized trial at 16 different medical centers (n = 160 patients) compared the order of testing (WATS^{3D} followed by biopsy sampling versus biopsy sampling followed by WATS^{3D}) to detect high-grade dysplasia/esophageal adenocarcinoma (HGD/EAC). The authors also

stated secondary aims of determining the amount of additional time required for WATS^{3D} and the ability of each procedure to separately detect neoplasia. The order of the procedures was not statistically relevant. The use of WATS^{3D} as an adjunct to biopsy did result in a 14.4% absolute increase in the number of HGD/EAC cases detected. The authors noted that WATS^{3D}, on average, adds 4.5 minutes to the total procedure time. They conclude that “Results of this multicenter, prospective, randomized trial demonstrate that the use of WATS in a referral BE population increases the detection of HGD/EAC.”³⁷

Diehl, et al. (2021) studied the impact of TissueCypher BE assay on clinical decisions in the management of BE patients. TissueCypher was ordered for 60 patients with BE and the impact of the test was assessed. TissueCypher results impacted 55.0% of management decisions, resulting in either upstaging or downstaging of treatment. The authors note that “In 21.7% of patients, the test upstaged the management approach, resulting in endoscopic eradication therapy or shorter surveillance interval. The test downstaged the management approach in 33.4% of patients, leading to surveillance rather than EET. In the subset of patients whose management plan was changed, upstaging was associated with a high-risk TissueCypher result, and downstaging was associated with a low-risk result.”³⁸ The authors conclude that TissueCypher will help target EET for high risk patients and reduce unneeded procedures in low-risk patients.³⁸

Wechsler, et al. (2021) studied the clinical utility of noninvasive biomarkers to identify EoE in children and predict esophageal eosinophilia. Blood/urine was collected from 183 children and several biomarkers were measured including Absolute eosinophil count (AEC), plasma eosinophil-derived neurotoxin (EDN), eosinophil cationic protein (ECP), major basic protein-1 (MBP-1), galectin-10 (CLC/GAL-10), Eotaxin-2 and Eotaxin-3, and urine osteopontin (OPN) and matrix metalloproteinase-9 (MMP-9). According to the results, all plasma and urine biomarkers were increased in EoE. A panel that included all the other biomarkers was superior to measuring only AEC alone. AEC, CLC/GAL-10, ECP, and MBP-1 were significantly decreased in patients with esophageal eosinophil counts <15/hpf in response to treatment. AEC combined with MBP-1 best predicted the esophageal eosinophil counts. The authors conclude that eosinophil-associated proteins along with AEC are superior to AEC alone in distinguishing EoE and predicting eosinophil counts.³⁹

VI. Guidelines and Recommendations

United European Gastroenterology (UEG), The European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), the European Academy of Allergy and Clinical Immunology (EAACI), and the European Society of Eosinophilic Oesophagitis (EUREOS)

These joint guidelines were published by a task force of 21 physicians and researchers for eosinophilic esophagitis (EoE). In it, they note that noninvasive biomarkers (inflammatory factors, total IgE, chemokines, tryptase, et al) are “not accurate” to diagnose or monitor EoE. They remark that absolute serum eosinophil count fared best in correlating with severity of disease but had a diagnostic accuracy of 0.754. The guidelines state that histology is necessary for monitoring. The String Test was also mentioned as having good preliminary results but required further corroboration.⁴⁰

European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)

The ESPGHAN also released guidelines on the diagnosis and management of EoE in children. “EoE is defined as a chronic, local inflammatory disease of the esophagus, which may cause symptoms of esophageal dysfunction, and is characterized histologically by predominantly eosinophilic infiltrates in

the absence of alternative causes of eosinophilic inflammation.” The ESPGHAN clarifies that “Non-Response to PPI is no longer part of the definition of EoE.”⁴¹ The ESPGHAN lists the following recommendations for diagnosis:

Endoscopy and other invasive tests:

- “ESPGHAN EGID WG recommends using endoscopic findings as supportive evidence when evaluating suspected EoE.
- “ESPGHAN EGID WG recommends that esophageal biopsies should be performed whenever a diagnosis of EoE is considered, regardless of the endoscopic appearance of the esophagus.”
- “ESPGHAN EGID WG recommends upper GI endoscopy with biopsies from the upper and lower levels of the esophagus (at least six, particularly targeting visible lesions) for the diagnosis and follow-up of childhood EoE.” “Practice points: The EoE Endoscopic Reference Score (EREFS) is currently the most valid and reliable endoscopic metric and can be used in conjunction with symptoms and histology as supportive evidence at diagnosis and when assessing response to treatment in pediatric EoE.”
- “ESPGHAN EGID WG recommends against the use of pH/impedance monitoring in the diagnosis of EoE, however, it may be useful in select cases to identify associated gastroesophageal reflux.”

Histology

- “ESPGHAN EGID WG recommends the peak value of 15 eos/HPF as the cut-off value in esophageal biopsy specimens, for the histological diagnosis of EoE in an appropriate clinical context.”
- “ESPGHAN EGID WG recommends the use of a standardized eosinophil density reporting tool.”
- “ESPGHAN EGID WG recommends converting eos/HPF values to either eos/mm² or to a standardized HPF size (CEGIR HPF) to enable comparison of eosinophil densities examined under different microscopes and for collaborative research or consultation: $\text{eos/HPF} \times 1/(\text{area of microscope HPF in mm}^2) = \text{eos/mm}^2$.” “Practice points: Isolated lower esophageal eosinophilia may pose a higher diagnostic challenge than upper esophageal involvement.”

Allergy testing

- “ESPGHAN EGID WG recommends against using available allergy tests to predict dietary triggers of EoE.”

Biomarkers and non-endoscopic techniques

- “The ESPGHAN EGID WG recommends against the use of currently available biomarkers as the sole basis for the diagnosis or management of pediatric EoE patients.”⁴²

American Gastroenterological Association (AGA) and the Joint Task Force on Allergy-Immunology Practice Parameters (JTF) guideline

Regarding allergy-based testing for the purpose of identifying food triggers in patients with Eosinophilic Esophagitis, the AGA/JTF suggest an allergy-based elimination diet over no treatment. The task force notes that “due to the potential limited accuracy of currently available, allergy-based testing for the identification of specific food triggers, patients may prefer alternative medical or dietary therapies to an exclusively testing-based elimination. An important limitation of the studies available so far “involves

the degree of inconsistency due to different testing techniques (e.g., skin-prick testing, serum-specific IgE testing, patch testing, or combinations of these) used in different studies.” Additionally, a “sensitivity analysis failed to show any statistically significant difference between studies that used patch testing and those that did not.”⁴³

Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference

These newly published international diagnostic criteria primarily include endoscopic findings. Although the guidelines emphasize ruling out other diagnoses (in which biomarkers may be useful), it does not mention any serum or genetic factors for EoE itself.⁶

National Comprehensive Cancer Network (NCCN)

The NCCN notes four syndromes that predispose to an increased risk for esophageal and esophagogastric junction (EGJ) cancers; tylosis with non-epidermolytic palmoplantar keratoderma (PPK) with esophageal cancer (including Howel-Evans syndrome), familial Barrett esophagus (FBE), Bloom Syndrome (BS, *BLM* gene), and Fanconi Anemia (FA, *FANC A-E* genes). The *RHBDF2* gene has been associated with tylosis (with non-epidermolytic palmoplantar keratosis) for genetic risk assessment.

Though FBE may be associated with “one or more autosomally inherited dominant susceptibility alleles,” no gene has been validated. With regards to next generation sequencing, the NCCN concludes that “when limited tissue is available for testing, or the patient is unable to undergo a traditional biopsy, sequential testing of single biomarkers or use of limited molecular diagnostic panels may quickly exhaust the sample. In these scenarios, comprehensive genomic profiling via a validated NGS assay performed in a CLIA-approved laboratory may be used for the identification of *HER2* amplification, MSI [microsatellite instability], MMR deficiency, TMB, *NTRK* gene fusions, *RET* gene fusions, and *BRAF v600E* mutations. The use of IHC/ISH/targeted PCR should be considered first followed by NGS testing when appropriate.”⁵

Under microsatellite instability (MSI) and mismatch repair testing, the NCCN recommends “universal testing for MSI by PCR, NGS, or MMR by IHC should be performed for all newly diagnosed esophageal and EGJ cancers.”

For squamous cell carcinoma, the NCCN recommends performing universal testing for microsatellite instability (MSI) by PCR/NGS or MMR by IHC in all newly diagnosed patients. It is also recommended that PD-L1 testing (if not done previously) if advanced/metastatic cancer is suspected. They also note that NGS may be considered via validated assay.⁵

Liquid biopsy aids in identifying genetic mutations in solid cancers by looking at circulating tumor DNA (ctDNA) in blood and can be used in those with advanced disease who cannot undergo clinical biopsies for disease surveillance and management. Detecting mutations in DNA from esophageal and EGJ carcinomas “can identify targetable alterations or the evolution of clones with altered treatment response profiles.” The NCCN has also stated that “a negative result should be interpreted with caution, as this does not exclude the presence of tumor mutations or amplifications.”⁵

The NCCN notes that “testing for MSI by PCR/NGS or MMR [mismatch repair] by IHC should be considered on locally advanced, recurrent, or metastatic esophageal and EGJ cancers in patients who are candidates for treatment with programmed cell death protein 1 (PD-1) inhibitors.”

The NCCN also identifies several targeted therapeutic agents currently approved by the FDA: trastuzumab, pembrolizumab/nivolumab, and entrectinib/larotrectinib. Trastuzumab is based on *HER2* overexpression (NCCN notes that an approved biologic or biosimilar drug to trastuzumab is also appropriate for use) and pembrolizumab can also be added to the regimen for treating *HER2*, notwithstanding any contraindications.

Treatment with trastuzumab is based on testing for *HER2* expression. Treatment with pembrolizumab or nivolumab is based on “testing for MSI by PCR/NGS or MMR by IHC, PD-L1 expression by IHC, or high TMB by NGS.” Select TRK inhibitors have also been FDA-approved for *NTRK* gene fusion-positive tumors. Additionally, selpercatinib can be used therapeutically for *RET* gene-related tumors and dabrafenib/trametinib for tumors with *BRAF V600E* mutations.⁵

Genetic biomarkers such as aneuploidy and loss of p53 heterozygosity have been proposed as useful for identifying increased risk of progression in BE patients, but the NCCN remarks that these biomarkers require “further prospective evaluation as predictors of risk for the development of HGD [high-grade dysplasia] and adenocarcinoma of the esophagus in patients with Barrett esophagus.”⁵

The NCCN notes that wide-area transepithelial sampling (WATS) has been used to detect esophageal carcinomas in BE patients. They state, “The use of wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS3D), a relatively new sampling technique combining an abrasive brush biopsy of the Barrett esophagus mucosa with computer-assisted pathology analysis to highlight abnormal cells, may help increase the detection of esophageal dysplasia in patients with Barrett esophagus.” They go on to cite the 2017 study by Vennalaganti and colleagues that shows a 14.4% increase in the number of additional cases of HGD/esophageal adenocarcinoma captured by using WATS. However, the NCCN remarks that the “utility and accuracy of WATS for detecting HGD/adenocarcinoma in patients with Barrett esophagus needs to be evaluated in larger phase III randomized trials.”⁵

American Society for Gastrointestinal Endoscopy (ASGE)

The ASGE recommends the use of WATS3D as an adjunct to “Seattle protocol biopsy sampling” in patients with known or suspected BE (conditional recommendation, low quality of evidence). The society stated that they had downrated the certainty of the recommendation due to possible risk bias, inconsistency, and indirectness of the studies that were available at the time of publication since some of the studies had included LGD (whereas others had not) and many of the studies had been sponsored by the test’s manufacturer. The society also had noted that, as of the date of publication, no studies addressing the cost-effectiveness of WATS-3D had been published.⁴¹ It should be noted that since the publication of these guidelines the 2020 cost-effectiveness study by Singer and Smith (2020) has been published.

Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Technology and Value Assessment Committee (TAVAC)

The TAVAC of SAGES evaluated WATS^{3D} and published their findings and recommendations within the journal *Surgical Endoscopy* in 2020. They note that WATS^{3D} is not recommended “as a stand-alone substitute for cold forcep biopsies.” Within their expert panel recommendation section:

- They state that no significant morbidity or mortality is associated with the testing.

- They also state that “WATS^{3D} increases diagnostic yield by 38 – 150% for Barrett’s Esophagus, by 40 – 150% for Low Grade Dysplasia; and by 420% for High Grade Dysplasia; when compared to forceps biopsy alone.”
- WATS^{3D} testing also “has very high inter-observer agreement for the pathological diagnosis of non-dysplastic and dysplastic Barrett’s Esophagus.”

Regarding value, “Increased detection of pre-malignant diseases of the esophagus by the adjunctive use of WATS^{3D} supports screening and surveillance by the adjunctive use of WATS^{3D} during upper endoscopy in appropriate patients.”⁴⁴

American Foregut Society (AFS)

The AFS published a white paper reviewing WATS^{3D} in 2020. After reviewing the literature, they state, “The American Foregut Society Board has concluded that there are sufficient data to support the routine use of WATS^{3D} technology in the diagnosis and ongoing evaluation of Barrett’s esophagus.”⁴⁵

American College of Gastroenterology (ACG)

In 2022, the ACG updated the Barrett’s Esophagus guideline and offered recommendations for the diagnosis, screening, surveillance, and endoscopic and medical therapy of BE. No recommendations were made regarding chemoprevention or use of “biomarkers” in routine practice due to “insufficient data.”

Studies do suggest that “biomarkers may be better than routine histology alone” in helping to predict the progression of cancer. However, the ACG notes that no single prediction tool or panel to predict disease progression has been established as having clear clinical utility. There have not been sufficient studies to evaluate the combination of clinical and biomarker variables.

The ACG could not recommend “routine use of p53 IHC or TissueCypher for risk stratification in patients with BE undergoing surveillance” due to unclear clinical validity.⁴⁶

However, the panel did not completely dissuade providers from the use of biomarkers under certain conditions since the predictive performance “has been shown to be better in some cases than the histologic diagnosis.” In the future, and with more clinical studies, this may mean that biomarkers could have predictive value in a subset of patients with BE without dysplasia.⁴⁶

In 2025, ACG released guidelines of the diagnosis and management of EoE. The guidelines include the following recommendations for diagnosis of EoE:

- “We recommend that EoE is diagnosed based on the presence of symptoms of esophageal dysfunction and at least 15 eosinophils per high-power field (eos/hpf) on esophageal biopsy, after evaluating for non-EoE disorders that cause or potentially contribute to esophageal eosinophilia (quality of evidence: low; strength of recommendation: strong).”
- “We recommend using a systematic endoscopic scoring system (e.g., the EoE Endoscopic Reference Score [EREFS]) to characterize endoscopic findings of EoE at every endoscopy (quality of evidence: low; strength of recommendation: strong).”
- “We recommend obtaining at least 6 esophageal biopsies from at least 2 esophageal levels (e.g., proximal/mid and distal), targeting EoE endoscopic findings, if possible, to assess for histologic features consistent with EoE (quality of evidence: low; strength of recommendation: strong).”

- “We recommend that eosinophil counts be quantified on esophageal biopsies from every endoscopy performed for EoE (quality of evidence: low; strength of recommendation: strong).”⁴⁷

European Society for Medical Oncology (ESMO)

No form of molecular testing for diagnosis or risk assessment of esophageal cancer is mentioned in the ESMO 2022 guideline.⁴⁸ The 2022 guideline does include a supplementary table listing biomarkers and molecular targets for precision medicines and corresponding scores for outcomes.⁴⁹

Biomarker or genomic alteration	Method of detection	Drug match	ESCAT score
HER2	IHC for <i>HER2</i> protein expression or ISH for <i>HER2</i> gene amplification	Anti- <i>HER2</i> antibodies (e.g. trastuzumab)	I-A (alteration-drug match is associated with improved outcome with evidence from randomised clinical trials showing the alteration-drug match in a specific tumour type results in a clinically meaningful improvement of a survival end point)
PD-L1	Combined Positive Score (CPS) or Tumour Positive Score (TPS)	PD-1 inhibitors (e.g. pembrolizumab, nivolumab)	
MSI	High Microsatellite Instability (MSI-H)	PD-1 inhibitors (e.g. nivolumab, pembrolizumab)	I-C (alteration-drug match is associated with improved outcome with evidence from clinical trials across tumour types or basket clinical trials showing clinical benefit associated with the alteration-drug match, with similar benefit observed across tumour types)

Obermannová, et al. (2022)

Pan-Asian adapted ESMO Clinical Practice Guidelines: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

The only biomarker mentioned in these guidelines is *HER2*; intended “to select patients with metastatic esophageal adenocarcinoma for treatment with...trastuzumab.” The guidelines go on to state that evidence for the role of other biomarkers or agents is “limited.”⁵⁰

VII. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the

Medicare search website <https://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

VIII. Applicable CPT/HCPCS Procedure Codes

CPT	CPT Description
81194	NTRK (neurotrophic receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis
81210	BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, colon cancer, melanoma), gene analysis, V600 variant(s)
81301	Microsatellite instability analysis (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) of markers for mismatch repair deficiency (eg, BAT25, BAT26), includes comparison of neoplastic and normal tissue, if performed
81404	Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis)
81405	Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis)
81406	Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons)
81479	Unlisted molecular pathology procedure
88104	Cytopathology, fluids, washings or brushings, except cervical or vaginal; smears with interpretation
88271	Molecular cytogenetics; DNA probe, each (eg, FISH)
88272	Molecular cytogenetics; chromosomal in situ hybridization, analyze 3-5 cells (eg, for derivatives and markers)
88273	Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)
88274	Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells
88275	Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells
88341	Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)
88342	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure
88344	Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure

CPT	CPT Description
88360	Morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure; manual
88361	Morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure; using computer-assisted technology
88367	Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), using computer-assisted technology, per specimen; initial single probe stain procedure
88368	Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; initial single probe stain procedure
88369	Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)
88373	Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), using computer-assisted technology, per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)
88374	Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), using computer-assisted technology, per specimen; each multiplex probe stain procedure
88377	Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; each multiplex probe stain procedure
0095U	Eosinophilic esophagitis, 2 protein biomarkers (Eotaxin-3 [CCL26 {C-C motif chemokine ligand 26}] and major basic protein [PRG2 {proteoglycan 2, pro eosinophil major basic protein}]), enzyme-linked immunosorbent assays (ELISA), specimen obtained by esophageal string test device, algorithm reported as probability of active or inactive eosinophilic esophagitis Proprietary test: Esophageal String Test™ (EST) Lab/Manufacturer: Cambridge Biomedical, Inc.
0108U	Gastroenterology (Barrett's esophagus), whole slide–digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer Proprietary test: TissueCypher® Barrett's Esophagus Assay Lab/Manufacturer: Cernostics
0114U	Gastroenterology (Barrett's esophagus), VIM and CCNA1 methylation analysis, esophageal cells, algorithm reported as likelihood for Barrett's esophagus Proprietary test: EsoGuard™ Lab/Manufacturer: Lucid Diagnostics
0398U	Gastroenterology (Barrett esophagus), P16, RUNX3, HPP1, and FBN1 DNA methylation analysis using PCR, formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as risk score for progression to high-grade dysplasia or cancer Proprietary test: ESOPREDICT® Barrett's Esophagus Risk Classifier Assay Lab/Manufacturer: Capsulomics, Inc d/b/a Previsé
0506U	Gastroenterology (Barrett's esophagus), esophageal cells, DNA methylation analysis by next-generation sequencing of at least 89 differentially methylated genomic regions, algorithm reported as likelihood for Barrett's esophagus

CPT	CPT Description
	Proprietary test: EndoSign® Barrett's Esophagus Test Lab/Manufacturer: Cytel Health Inc

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

IX. Evidence-based Scientific References

1. Zhang X, Patil D, Odze RD, et al. The microscopic anatomy of the esophagus including the individual layers, specialized tissues, and unique components and their responses to injury. *Annals of the New York Academy of Sciences*. Dec 2020;1434(1):304-318. doi:10.1111/nyas.13705
2. Bonis PAL, Gupta SK. Clinical manifestations and diagnosis of eosinophilic esophagitis. Updated January 15, 2025. <https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-eosinophilic-esophagitis>
3. Spechler S. Barrett's esophagus: Epidemiology, clinical manifestations, and diagnosis. Updated April 30, 2024. <https://www.uptodate.com/contents/barretts-esophagus-epidemiology-clinical-manifestations-and-diagnosis>
4. Saltzman JR, Gibson MK. Clinical manifestations, diagnosis, and staging of esophageal cancer. Updated May 31, 2023. <https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-staging-of-esophageal-cancer>
5. NCCN. Esophageal and Esophagogastric Junction Cancers. Updated December 20, 2024. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
6. Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. *Gastroenterology*. Oct 2018;155(4):1022-1033.e10. doi:10.1053/j.gastro.2018.07.009
7. Rothenberg ME. Eosinophilic esophagitis (EoE): Genetics and immunopathogenesis. Updated January 10, 2023. <https://www.uptodate.com/contents/eosinophilic-esophagitis-eoe-genetics-and-immunopathogenesis>
8. Sherrill JD, Rothenberg ME. Genetic and epigenetic underpinnings of eosinophilic esophagitis. *Gastroenterology clinics of North America*. Jun 2014;43(2):269-80. doi:10.1016/j.gtc.2014.02.003
9. Wen T, Stucke EM, Grotjan TM, et al. Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. *Gastroenterology*. Dec 2013;145(6):1289-99. doi:10.1053/j.gastro.2013.08.046
10. Shoda T, Wen T, Aceves SS, et al. Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. *The lancet Gastroenterology & hepatology*. Jul 2018;3(7):477-488. doi:10.1016/s2468-1253(18)30096-7
11. Ackerman SJ, Kagalwalla AF, Hirano I, et al. One-Hour Esophageal String Test: A Nonendoscopic Minimally Invasive Test That Accurately Detects Disease Activity in Eosinophilic Esophagitis. *The American journal of gastroenterology*. Oct 2019;114(10):1614-1625. doi:10.14309/ajg.0000000000000371
12. EnteroTrack. The EnteroTracker®. <https://enterotrack.com/our-technology>
13. Vollmer RT. A review of the incidence of adenocarcinoma detected during surveillance for Barrett's esophagus. *Human pathology*. Feb 2019;84:150-154. doi:10.1016/j.humpath.2018.09.016
14. Interpace. An Innovative Diagnostic Tool for Barrett's Esophagus Patients. <https://barregen.com/>
15. Trindade AJ, McKinley MJ, Alshelleh M, et al. Mutational load may predict risk of progression in patients with Barrett's oesophagus and indefinite for dysplasia: a pilot study. *BMJ Open Gastroenterology*. 2019;6(1):e000268. doi:10.1136/bmjgast-2018-000268

16. Castle Biosciences. What is the TissueCypher® Barrett's Esophagus Assay? <http://www.cernostics.com/products/>
17. Lucid Diagnostics. Esoguard. <https://www.luciddx.com/precancer-detection/esoguard>
18. CDx Diagnostics. WATS3D empowers physicians to preempt cancer. <https://www.cdxdiagnostics.com/wats3d>
19. Gibson MK. Epidemiology and risk factors for esophageal cancer. Updated March 6, 2025. <https://www.uptodate.com/contents/epidemiology-and-risk-factors-for-esophageal-cancer>
20. Testa U, Castelli G, Pelosi E. Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell Compartment and Clonal Evolution. *Medicines (Basel, Switzerland)*. Sep 14 2017;4(3)doi:10.3390/medicines4030067
21. Visser E, Franken IA, Brosens LA, Ruurda JP, van Hillegersberg R. Prognostic gene expression profiling in esophageal cancer: a systematic review. *Oncotarget*. Jan 17 2017;8(3):5566-5577. doi:10.18632/oncotarget.13328
22. Gonzaga IM, Soares Lima SC, Nicolau MC, et al. TFF1 hypermethylation and decreased expression in esophageal squamous cell carcinoma and histologically normal tumor surrounding esophageal cells. *Clinical epigenetics*. 2017;9:130. doi:10.1186/s13148-017-0429-0
23. McLaren PJ, Barnes AP, Terrell WZ, et al. Specific gene expression profiles are associated with a pathologic complete response to neoadjuvant therapy in esophageal adenocarcinoma. *American journal of surgery*. May 2017;213(5):915-920. doi:10.1016/j.amjsurg.2017.03.024
24. Visaggi P, Barberio B, Ghisa M, et al. Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence. *Cancers (Basel)*. Jun 24 2021;13(13)doi:10.3390/cancers13133162
25. Li J, Qi Z, Hu YP, Wang YX. Possible biomarkers for predicting lymph node metastasis of esophageal squamous cell carcinoma: a review. *The Journal of international medical research*. Feb 2019;47(2):544-556.
26. Plum PS, Gebauer F, Krämer M, et al. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma. *BMC Cancer*. Jan 8 2019;19(1):38. doi:10.1186/s12885-018-5242-4
27. Frankell AM, Jammula S, Li X, et al. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. *Nature genetics*. Mar 2019;51(3):506-516. doi:10.1038/s41588-018-0331-5
28. Hao J, Critchley-Thorne R, Diehl DL, Snyder SR. A Cost-Effectiveness Analysis Of An Adenocarcinoma Risk Prediction Multi-Biomarker Assay For Patients With Barrett's Esophagus. *ClinicoEconomics and outcomes research : CEOR*. 2019;11:623-635. doi:10.2147/ceor.S221741
29. Eluri S, Klaver E, Duits LC, Jackson SA, Bergman JJ, Shaheen NJ. Validation of a biomarker panel in Barrett's esophagus to predict progression to esophageal adenocarcinoma. *Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus*. Nov 1 2018;31(11)doi:10.1093/dote/doy026
30. Moinova HR, LaFramboise T, Lutterbaugh JD, et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. *Science translational medicine*. Jan 17 2018;10(424)doi:10.1126/scitranslmed.aa05848
31. Critchley-Thorne RJ, Duits LC, Prichard JW, et al. A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. Jun 2016;25(6):958-68. doi:10.1158/1055-9965.Epi-15-1164
32. Smith MS, Ikonomi E, Bhuta R, et al. Wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS) markedly improves detection of esophageal dysplasia and Barrett's

- esophagus: analysis from a prospective multicenter community-based study. *Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus*. Mar 1 2019;32(3)doi:10.1093/dote/doy099
33. Singer ME, Smith MS. Wide Area Transepithelial Sampling with Computer-Assisted Analysis (WATS(3D)) Is Cost-Effective in Barrett's Esophagus Screening. *Dig Dis Sci*. Jun 23 2020;doi:10.1007/s10620-020-06412-1
 34. Anandasabapathy S, Sontag S, Graham DY, et al. Computer-assisted brush-biopsy analysis for the detection of dysplasia in a high-risk Barrett's esophagus surveillance population. *Dig Dis Sci*. Mar 2011;56(3):761-6. doi:10.1007/s10620-010-1459-z
 35. Gross SA, Smith MS, Kaul V. Increased detection of Barrett's esophagus and esophageal dysplasia with adjunctive use of wide-area transepithelial sample with three-dimensional computer-assisted analysis (WATS). *United European Gastroenterol J*. May 2018;6(4):529-535. doi:10.1177/2050640617746298
 36. Johanson JF, Frakes J, Eisen D. Computer-assisted analysis of abrasive transepithelial brush biopsies increases the effectiveness of esophageal screening: a multicenter prospective clinical trial by the EndoCDx Collaborative Group. *Dig Dis Sci*. Mar 2011;56(3):767-72. doi:10.1007/s10620-010-1497-6
 37. Vennalaganti PR, Kaul V, Wang KK, et al. Increased detection of Barrett's esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial. *Gastrointest Endosc*. Feb 2018;87(2):348-355. doi:10.1016/j.gie.2017.07.039
 38. Diehl DL, Khara HS, Akhtar N, Critchley-Thorne RJ. TissueCypher Barrett's esophagus assay impacts clinical decisions in the management of patients with Barrett's esophagus. *Endosc Int Open*. Mar 2021;9(3):E348-e355. doi:10.1055/a-1326-1533
 39. Wechsler JB, Ackerman SJ, Chehade M, et al. Noninvasive biomarkers identify eosinophilic esophagitis: A prospective longitudinal study in children. *Allergy*. 2021;76(12):3755-3765. doi:10.1111/all.14874
 40. Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. *United European Gastroenterol J*. Apr 2017;5(3):335-358. doi:10.1177/2050640616689525
 41. Qumseya B, Sultan S, Bain P, et al. ASGE guideline on screening and surveillance of Barrett's esophagus. *Gastrointestinal Endoscopy*. 2019;90(3):335-359.e2. doi:10.1016/j.gie.2019.05.012
 42. Amil-Dias J, Oliva S, Papadopoulou A, et al. Diagnosis and management of eosinophilic esophagitis in children: An update from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). *J Pediatr Gastroenterol Nutr*. Aug 2024;79(2):394-437. doi:10.1002/jpn3.12188
 43. Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. *Gastroenterology*. 2020;158(6):1776-1786. doi:10.1053/j.gastro.2020.02.038
 44. Docimo S, Jr., Al-Mansour M, Tsuda S. SAGES TAVAC safety and efficacy analysis WATS(3D) (CDx Diagnostics, Suffern, NY). *Surg Endosc*. Mar 11 2020;doi:10.1007/s00464-020-07503-w
 45. AFS. Wide Area Transepithelial Sampling with Computer Assisted 3D Analysis (WATS3D). American Foregut Society. <https://www.americanforegutsociety.org/assets/docs/CDX-white-paper.pdf>
 46. Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. *The American journal of gastroenterology*. Apr 1 2022;117(4):559-587. doi:10.14309/ajg.0000000000001680
 47. Dellon ES, Muir AB, Katzka DA, et al. ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis. *The American journal of gastroenterology*. Jan 1 2025;120(1):31-59. doi:10.14309/ajg.0000000000003194

48. Obermannová R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up^{#x2606;}. *Annals of Oncology*. 2022;33(10):992-1004. doi:10.1016/j.annonc.2022.07.003
49. ESMO. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. SUPPLEMENTARY MATERIAL. 2022;
50. Muro K, Lordick F, Tsushima T, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. *Annals of oncology : official journal of the European Society for Medical Oncology*. Jan 1 2019;30(1):34-43. doi:10.1093/annonc/mdy498

X. Review/Revision History

Effective Date	Summary
07/01/2025	Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references. Literature review did not necessitate any modifications to coverage criteria. The following edits were made for clarity and consistency: CC3, added “methodology” after “other in situ hybridization (ISH)” Note edited to change “5” to “two” to align with guidance in R2162: “Note: For two or more gene tests being run on the same platform, please refer to AHS-R2162-Reimbursement Policy.” Added CPT code 81210 Off-cycle coding modification: Revised CPT code 0095U (effective date 1/1/2025) Off-cycle coding modification: Added CPT code 0506U (effective date 10/1/2024) Off-cycle coding modification: Removed CPT code 88112, 88160, 88305, 88312 Policy and translation were reviewed by the Medical Director who determined that CPT codes 88112, 88160, 88305, 88312 are not applicable/appropriate for CC6 and should be removed from the coverage criteria. Since these codes are only mapped to CC6, they will be removed from the policy.
12/01/2024	Initial Policy Implementation